Corcept Therapeutics (CORT)
(Real Time Quote from BATS)
$45.38 USD
+0.13 (0.29%)
Updated Oct 11, 2024 12:16 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
CORT 45.38 +0.13(0.29%)
Will CORT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
5 Stocks With Recent Price Strength Amid October Volatility
Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark
Here's Why Investors Should Consider Buying Corcept Stock Now
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
Other News for CORT
Biotech Alert: Searches spiking for these stocks today
Corcept Therapeutics price target raised by $11 at Truist, here's why
Corcept Therapeutics (CORT) Receives a Buy from Truist Financial
Piper Sandler’s Triple Select Stocks for September
Biotech Alert: Searches spiking for these stocks today